Hot Features
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastati... CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors. The company was incorporated in 2017 and is headquartered in Houston, Texas. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.39 | -7.9107505071 | 4.93 | 5.34 | 4.54 | 17933 | 5.0973571 | CS |
| 4 | -2.19 | -32.5408618128 | 6.73 | 7.3799 | 4.54 | 86583 | 5.23066034 | CS |
| 12 | 1.99 | 78.0392156863 | 2.55 | 10.54 | 1.9 | 1531142 | 7.70612587 | CS |
| 26 | -2.71 | -37.3793103448 | 7.25 | 10.54 | 1.9 | 738450 | 7.64608664 | CS |
| 52 | 3.47 | 324.299065421 | 1.07 | 10.588 | 0.6594 | 404268 | 7.2374015 | CS |
| 156 | 2.23 | 96.5367965368 | 2.31 | 10.588 | 0.066 | 4137830 | 0.48231195 | CS |
| 260 | 2.55 | 128.140703518 | 1.99 | 10.588 | 0.066 | 2840652 | 0.61623757 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.